论文信息 - Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083 - 字舞流文

Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083

A. Chen | D. Gandara | M. Goetz | J. Sparano | R. Nanda | B. Arun | T. Moynihan | P. Frankel | H. Chew | J. Weitzel | G. Somlo | J. Mortimer | R. Piekarz | J. Herzog | S. Sand | J. Beumer | L. Vahdat | A. Hurria | Lily R. Van Tongeren | Katherine V. Ferry-Galow | H. Harvey | Cynthia X. Ma | Agustin A. Garcia | L. Cream | E. Newman | T. Cigler | C. Ruel